Oncology development and trial operations
LANT Nanotherapy: The Work Behind a Credible Human Trial
What LANT’s reported FDA Breakthrough Device designation means for human evidence, safe delivery, oncology trial readiness and CRA and CTM responsibilities.
By Lampgen Clinical Research

4 min read · estimated
What the source reported
The Ora Lee Smith Cancer Research Foundation reports FDA Breakthrough Device designation for Dr. Hadiyah-Nicole Green’s Laser-Activated Nano-Therapy (LANT). Its treatment-availability page describes plans to move into human research. [1, 5]
The designation can facilitate development and prioritized review; it is not marketing approval or proof of patient benefit. [2]
The laboratory result and its limits
The 2014 paper’s abstract describes intratumoral gold nanorods and a single near-infrared laser exposure in Cal 27 squamous-cell carcinoma xenografts. It reports approximately complete regression in about 90% of treated tumors during 10–15 days of assessment. [3, 4]
The observation supports further investigation of localized photothermal treatment. It cannot establish human safety, lasting disease control, effectiveness across tumor types or superiority to standard care.
This analysis uses the accessible published abstract, the foundation’s public disclosures and FDA guidance. The founder discussed the designation on World Cancer Day 2026; this is a development analysis rather than a claim of a new November designation. [6]
Translate the mechanism into records a site can produce
For a comparable investigational procedure, the protocol and supporting plans would need to define the delivery variables that matter. Proposed examples include material identity and accountability, injection location, device settings, calibration, exposure timing and operator qualification.
The appropriate measurements and thresholds belong to the sponsor’s clinical, engineering and regulatory teams. Monitoring should verify the resulting requirements rather than invent technical acceptance limits.
An oncology CRA needs a traceable way to connect the participant, treated lesion, procedure record, safety assessment and subsequent response evaluation. A CTM needs to know who resolves a missing or conflicting record before it affects the next decision.
Make safety follow-up part of site readiness
A future protocol should define how sites recognize, document and escalate relevant safety events, including complications the clinical team considers plausible for the procedure. Response assessment and recovery assessment answer different questions.
The team should be able to explain who takes a participant’s call after the procedure, who makes the medical assessment and how the information reaches the sponsor through the agreed process.
These are proposed readiness questions. Public material reviewed here does not establish that LANT has a particular human safety profile or that its team lacks these processes.
Investigate variation before interpreting it as biology
Consider an illustrative scenario: two centers report different local response patterns. Before attributing the difference to the therapy, a study team would examine lesion characteristics, treatment delivery, assessment timing and completeness of follow-up.
A useful SIGNAL™ question is whether a delivery discrepancy appears elsewhere and which function can investigate it. The study team should assign action through the sponsor’s process, then review subsequent records to see whether the intended change occurred.
This example is fictional. It does not imply a discrepancy, site issue or audit finding in LANT. Investigators retain medical decisions, and sponsors retain responsibility for their development and oversight plans.
Measure the full participation burden
A short exposure time in an animal study does not establish a short or low-cost human care pathway. Proposed planning measures include total visit time, travel, preparation, recovery contacts and follow-up requirements.
Sites should be selected and supported with the intended population in mind. Transportation, language services and the timing of permitted expense reimbursement can influence who has a practical opportunity to take part.
The foundation’s affordability mission is a development goal. Neither the nonprofit model nor the designation establishes an eventual treatment price, reimbursement decision or equitable access outcome. [1]
The next evidence milestones
The public pages reviewed do not provide human efficacy results or establish an enrolling study. The next review should seek a public trial record, a defined intended population, documented study readiness and human safety and outcome reporting. [5]
A designation does not itself establish that a specific human trial is authorized. Any required study approvals, device and material readiness, site preparation and funding remain distinct milestones.
Sponsors evaluating a staffing need can turn these questions into responsibilities: which records must be reviewed, which discrepancies require escalation, who can decide and how follow-up will be verified.
What this means for trial teams
For a comparable program, scope oncology CRA and CTM responsibilities around the actual protocol, procedure requirements, monitoring plan and decision ownership. Clinical operations cannot substitute for the medical, engineering or regulatory expertise the program requires.
Lampgen Clinical Research starts staffing discussions with the work an assignment must support: source traceability, coordinated escalation and documented follow-through. The delivery plan should make those responsibilities concrete before an assignment is agreed. [7]
Analysis by Tommy Lampley, Jr., M.S., Founder, Lampgen Clinical Research. Published November 17, 2026. This public-source commentary does not claim involvement in LANT or access to its regulatory correspondence.
Sources
- Ora Lee Smith Cancer Research Foundation — reported Breakthrough Device designation and development plans
- FDA — Breakthrough Devices Program, benefits and marketing standards
- Green et al., International Journal of Nanomedicine (2014), DOI 10.2147/IJN.S60648 — original paper record
- Stanford Health Care — accessible abstract of Green et al. (2014)
- Ora Lee Smith Cancer Research Foundation — treatment availability and plans for human trials
- Hadiyah-Nicole Green — World Cancer Day 2026 designation announcement
- Lampgen — oncology CRA staffing
- Related Tommy Lampley analysis — LANT and human evidence
- Lampgen — site readiness questions